Abstract
The aim of this work was to study the association of potential biomarkers with fast aortic stenosis (AS) progression. Patients with moderate-to-severe AS were classified as very fast progressors (VFP) if exhibited an annualized change in peak velocity (aΔVmax) ≥0.45m/s/year and/or in aortic valve area (aΔAVA) ≥−0.2cm2/year. Respective cut-off values of ≥0.3m/s/year and ≥−0.1cm2/year defined fast progressors (FP), whereas the remaining patients were non-fast progressors (non-FP). Baseline markers of lipid metabolism, inflammation, and cardiac overload were determined. Two hundred and nine patients (97 non-FP, 38 FP, and 74 VFP) were included. PCSK9 levels were significantly associated with VFP (OR 1.014 [95%CI 1.005-1.024], for every 10 ng/mL), as were active smoking (OR 3.48) and body mass index (BMI, OR 1.09), with an AUC of 0.704 for the model. PCSK9 levels, active smoking, and BMI were associated with very fast AS progression in our series, suggesting that inflammation and calcification participate in disease progression.
Similar content being viewed by others
References
Otto, C. M., & Prendergast, B. (2014). Aortic-valve stenosis — From patients at risk to severe valve obstruction. The New England Journal of Medicine, 371, 744–756.
Iung, B., & Vahanian, A. (2011). Epidemiology of valvular heart disease in the adult. Nature Reviews. Cardiology, 8, 162–172.
Généreux, P., Stone, G. W., O’Gara, P. T., Marquis-Gravel, G., Redfors, B., Giustino, G., Pibarot, P., Bax, J. J., Bonow, R. O., & Leon, M. B. (2016). Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. Journal of the American College of Cardiology, 67, 2263–2288.
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., Rosenhek, R., Sjögren, J., Tornos Mas, P., Vahanian, A., Walther, T., Wendler, O., Windecker, S., & Zamorano, J. L. (2017). Document. 2017 ESC/EACTS Guidelines on the management of valvular heart disease. European Heart Journal, 38, 2739–2791.
Taniguchi, T., Morimoto, T., Shiomi, H., Ando, K., Kanamori, N., Murata, K., Kitai, T., Kawase, Y., Izumi, C., Miyake, M., Mitsuoka, H., Kato, M., Hirano, Y., Matsuda, S., Nagao, K., Inada, T., Murakami, T., Takeuchi, Y., Yamane, K., Toyofuku, M., Ishii, M., Minamino-Muta, E., Kato, T., Inoko, M., Ikeda, T., Komasa, A., Ishii, K., Hotta, K., Higashitani, N., Kato, Y., Inuzuka, Y., Maeda, C., Jinnai, T., Morikami, Y., Sakata, R., & Kimura, T. (2015). Initial Surgical Versus Conservative Strategies in Patients with Asymptomatic Severe Aortic Stenosis. Journal of the American College of Cardiology, 66, 2827–2838.
Varadarajan, P., Kapoor, N., Bansal, R. C., & Pai, R. G. (2006). Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. The Annals of Thoracic Surgery, 82, 2111–2115.
Milin, A. C., Vorobiof, G., Aksoy, O., & Ardehali, R. (2014). Insights Into Aortic Sclerosis and Its Relationship With Coronary Artery Disease. Journal of the American Heart Association, 3, 1–12.
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O’Brien, K. D., Schoen, F. J., Towler, D. A., Yoganathan, A. P., & Otto, C. M. (2011). Calcific Aortic Valve Disease: Not Simply a Degenerative Process. Circulation., 124, 1783–1791.
Cho, K. I., Sakuma, I., Sohn, I. S., Jo, S. H., & Koh, K. K. (2018). Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease. Atherosclerosis., 277, 60–65.
Rajamannan, N. M., Subramaniam, M., Rickard, D., Stock, S. R., Donovan, J., Springett, M., Orszulak, T., Fullerton, D. A., Tajik, A. J., Bonow, R. O., & Spelsberg, T. (2003). Human aortic valve calcification is associated with an osteoblast phenotype. Circulation., 107, 2181–2184.
Baumgartner, H., Hung, J., Bermejo, J., Chambers, J. B., Edvardsen, T., Goldstein, S., Lancellotti, P., Lefevre, M., Miller, F., & Otto, C. M. (2017). Recommendations on the echocardiographic assessment of aortic valve stenosis: A focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European Heart Journal Cardiovascular Imaging, 18, 254–275.
Gómez, M., Ble, M., Cladellas, M., Molina, L., Comín-Colet, J., Enjuanes, C., Roqueta, C., Soler, C., & Bruguera, J. (2015). Effect of correction of anemia on echocardiographic and clinical parameters in patients with aortic stenosis involving a three-cuspid aortic valve and normal left ventricular ejection fraction. The American Journal of Cardiology, 116, 270–274.
Owens, D. S., Katz, R., Takasu, J., Kronmal, R., Budoff, M. J., & O’Brien, K. D. (2010). Incidence and progression of aortic valve calcium in the multi-ethnic study of atherosclerosis (MESA). The American Journal of Cardiology, 105, 701–708.
Navarese, E. P., Kołodziejczak, M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito, F., Sionis, A., & Ciccone, M. M. (2016). From proprotein convertase subtilisin/kexin type 9 to its inhibition: State-of-The-Art and clinical implications. Eur Hear J - Cardiovasc Pharmacother., 2, 44–53.
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O’connor, C., & Gurbel, P. A. (2016). Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome a narrative review. Annals of Internal Medicine, 164, 600–607.
Maxwell, K. N., Fisher, E. A., & Breslow, J. L. (2005). Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proceedings of the National Academy of Sciences, 102, 2069–2074.
Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah, N. G., & Prat, A. (2012). Gene Inactivation of PCSK9 Reduces Atherosclerosis in Mice. Circulation., 125, 894–901.
Liu, X., Suo, R., Chan, C. Z. Y., Liu, T., Tse, G., & Li, G. (2019). The immune functions of PCSK9: Local and systemic perspectives. Journal of Cellular Physiology, jcp.28612.
Wang, W. G., He, Y. F., Chen, Y. L., Zhao, F. M., Song, Y. Q., Zhang, H., Ma, Y. H., Guan, X., Zhang, W. Y., Chen, X. L., Liu, C., & Cong, H. L. (2016). Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study. The Journal of International Medical Research, 44, 865–874.
Salaun, E., Mahjoub, H., Dahou, A., Mathieu, P., Larose, É., Després, J. P., Rodés-Cabau, J., Arsenault, B. J., Puri, R., Clavel, M. A., & Pibarot, P. (2018). Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves. Journal of the American College of Cardiology, 72, 241–251.
Poggio, P., Songia, P., Cavallotti, L., Barbieri, S. S., Zanotti, I., Arsenault, B. J., Valerio, V., Ferri, N., Capoulade, R., & Camera, M. (2018). PCSK9 Involvement in Aortic Valve Calcification. Journal of the American College of Cardiology, 72, 3225–3227.
Aceña, Á., Franco Peláez, J. A., Pello Lázaro, A. M., Gonzalez Parra, E., Gonzalez Lorenzo, Ó., Martínez-Milla, J., Hernandez, I., Martín-Mariscal, M. L., Lopez Castillo, M., Kallmeyer, A., Lorenzo, O., González-Casaus, M. L., Egido, J., & Tuñón, J. (2020). PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research.
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016). PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis. The Journal of Clinical Endocrinology and Metabolism, 101, 3281–3287.
Mayne, J., Dewpura, T., Raymond, A., Cousins, M., Chaplin, A., Lahey, K. A., LaHaye, S. A., Mbikay, M., Ooi, T. C., & Chrétien, M. (2008). Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids in Health and Disease, 7, 1–9.
Mohler, E. R., Nichols, R., Harvey, W. P., Sheridan, M. J., Waller, B. F., & Waller, B. F. (1991). Development and progression of aortic valve stenosis: Atherosclerosis risk factors—a causal relationship? a clinical morphologic study. Clinical Cardiology, 14, 995–999.
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (2002). Clinical Factors Associated With Calcific Aortic Valve Disease. Cardiovascular Health Study. Journal of the American College of Cardiology, 29, 630–634.
Palta, S., Pai, A. M., Gill, K. S., & Pai, R. G. (2012). New Insights Into the Progression of Aortic Stenosis. Circulation., 101, 2497–2502.
Messner, B., & Bernhard, D. (2014). Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 509–515.
Eveborn, G. W., Schirmer, H., Lunde, P., Heggelund, G., Hansen, J. B., & Rasmussen, K. (2014). Assessment of risk factors for developing incident aortic stenosis: The Tromsø Study. European Journal of Epidemiology, 29, 567–575.
Rosa, M., Paris, C., Sottejeau, Y., Corseaux, D., Robin, E., Tagzirt, M., Juthier, F., Jashari, R., Rauch, A., Vincentelli, A., Staels, B., Van Belle, E., Susen, S., & Dupont, A. (2017). Leptin induces osteoblast differentiation of human valvular interstitial cells via the Akt and ERK pathways. Acta Diabetologica, 54, 551–560.
Kamath, A. R., & Pai, R. G. (2008). Risk factors for progression of calcific aortic stenosis and potential therapeutic targets. International Journal of Angiology, 17, 63–70.
Mathieu, P., Lemieux, I., & Després, J. P. (2010). Obesity, inflammation, and cardiovascular risk. Clinical Pharmacology and Therapeutics, 87, 407–416.
Rogge, B. P., Cramariuc, D., Lønnebakken, M. T., Gohlke-Bärwolf, C., Chambers, J. B., Boman, K., & Gerdts, E. (2013). Effect of overweight and obesity on cardiovascular events in asymptomatic aortic stenosis: A SEAS substudy (Simvastatin Ezetimibe in Aortic Stenosis). Journal of the American College of Cardiology, 62, 1683–1690.
Rosenhek, R., Binder, T., Porenta, G., Lang, I., Christ, G., Schemper, M., Maurer, G., & Baumgartner, H. (2002). Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis. The New England Journal of Medicine, 343, 611–617.
Eisenga, M. F., Zelle, D. M., Sloan, J. H., Gaillard, C. A. J. M., Bakker, S. J. L., & Dullaart, R. P. F. (2017). High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients. Diabetes Care, 40, 894–901.
Funding
This study was funded by the Fundació La Marató de TV3 (REF 2015-1910).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
All procedures performed in the present study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
The authors declare no competing interests.
Additional information
Associate Editor Craig M. Stolen oversaw the review of this article
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Clinical Relevance
• In this prospective study including 209 patients with asymptomatic moderate-to-severe degenerative AS, we found that active smoking, BMI, and levels of PCSK9 are predictors of a particularly fast progression of the disease. Our data suggest, therefore, that inflammation and subsequent calcification could be important mechanisms of AS progression.
• Our results are novel in that they suggest that PCSK9 levels could help in predicting a very rapid AS progression.
• Moreover, our results set the basis to assess the potential benefit of intensive preventive strategies to reduce modifiable risk factors such as smoking and BMI associated with fast AS progression.
Rights and permissions
About this article
Cite this article
Mateos, N., Gómez, M., Homar, A. et al. Plasmatic PCSK9 Levels Are Associated with Very Fast Progression of Asymptomatic Degenerative Aortic Stenosis. J. of Cardiovasc. Trans. Res. 15, 5–14 (2022). https://doi.org/10.1007/s12265-021-10138-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-021-10138-4